Viking Therapeutics (VKTX) Other Non Operating Income (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Other Non Operating Income data on file, last reported at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 41.06% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $29.7 million (down 32.71% YoY), and the FY2025 full-year result was $33.7 million, down 17.71% from the prior year.
• Other Non Operating Income retreated to $5.8 million in Q1 2026, from $7.1 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $11.8 million in Q2 2024 to a low of $142000.0 in Q1 2022.
• A 5-year average of $5.7 million and a median of $5.8 million in 2026 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income surged 2168.84% in 2023 and slumped 41.06% in 2026, its largest moves.
• Tracing VKTX's Other Non Operating Income over 5 years: stood at $724000.0 in 2022, then jumped by 546.41% to $4.7 million in 2023, then surged by 131.22% to $10.8 million in 2024, then plunged by 34.61% to $7.1 million in 2025, then slipped by 18.03% to $5.8 million in 2026.
• Business Quant data shows VKTX's Other Non Operating Income at $5.8 million in Q1 2026, $7.1 million in Q4 2025, and $7.8 million in Q3 2025.